Equillium: EQ504 Is the Hook — The Platform Could Be the Real Upside
Equillium is a clinical-stage biotech with a multi-cytokine pipeline anchored by EQ504 (AhR modulation for ulcerative colitis) and complementary assets (EQ001, EQ302). The stock trades around $1.83 with a market cap near $111M and roughly $10.7M in cash. Upcoming UC-focused KOL engagement, partnership work on an oral EQ302 formulation and improving…